Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (151-160 of 223) with videos related to

Pageof 23
Sort By:
The British Journal of Dermatology|March 4, 2026
Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alphaKirsty Hodgson, Joseph Inns, Gary Reynolds, et al.
JAMA Oncology|April 30, 2026
Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical TrialKim A Reiss, Mingyi Xia, Mwangala Akamandisa, et al.
Nature Cell Biology|January 11, 2022
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatinDragomir B Krastev, Shudong Li, Yilun Sun, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Cancer Discovery|March 15, 2015
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast CancersJohnathan Watkins, Daniel Weekes, Vandna Shah, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Nature Communications|August 1, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trialMagnus T Dillon, Emmanuel C Patin, Kabir Mohammed, et al.
Cancers|August 7, 2021
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell CarcinomaSaira Khalique, Sarah Nash, David Mansfield, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Molecular Cancer Therapeutics|November 15, 2017
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast CancerKalnisha Naidoo, Patty T Wai, Sarah L Maguire, et al.
Pageof 23

Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
The British Journal of Dermatology|March 4, 2026
Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alphaKirsty Hodgson, Joseph Inns, Gary Reynolds, et al.
JAMA Oncology|April 30, 2026
Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical TrialKim A Reiss, Mingyi Xia, Mwangala Akamandisa, et al.
Nature Cell Biology|January 11, 2022
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatinDragomir B Krastev, Shudong Li, Yilun Sun, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Cancer Discovery|March 15, 2015
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast CancersJohnathan Watkins, Daniel Weekes, Vandna Shah, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Nature Communications|August 1, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trialMagnus T Dillon, Emmanuel C Patin, Kabir Mohammed, et al.
Cancers|August 7, 2021
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell CarcinomaSaira Khalique, Sarah Nash, David Mansfield, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Molecular Cancer Therapeutics|November 15, 2017
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast CancerKalnisha Naidoo, Patty T Wai, Sarah L Maguire, et al.
Pageof 23